Superworth

Stereotaxis STXS

Medical - Devices, Healthcare
$0.88
+2.03%
Market cap
$88.2M
PE
n/m
a loss over the last year
Forward PE
n/m
not a meaningful number
Price to sales
2.9×
EV/EBIT
n/m
a loss over the last year
Revenue, 12 months
$30.1M
−5% on a year ago
Net margin
−74.2%
Free cash flow yield
−17.6%

Stereotaxis trades at 2.9× sales. Its trailing earnings are negative, so it has no PE. Revenue was $30.1M over the last twelve months, down 5% on a year earlier with a −74% net margin.

Charts

Financials

Income statement for STXS, by quarter
Income statementQ3 FY23Q4 FY23Q1 FY24Q2 FY24Q3 FY24Q4 FY24Q1 FY25Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26
$7.8M+2%$4.6M−38%$6.9M+5%$4.5M−43%$9.2M+18%$6.3M+39%$7.5M+9%$8.8M+95%$7.5M−19%$8.6M+36%$6.3M−16%$7.7M−13%
Cost of revenue$3.7M+21%$1.8M−39%$2.9M+9%$1.2M−68%$5.1M+36%$3.1M+71%$3.4M+17%$4.2M+255%$3.4M−34%$4.3M+38%$2.5M−27%$3.2M−25%
Gross profit$4.1M−11%$2.7M−37%$4M+2%$3.3M−21%$4.1M+1%$3.2M+18%$4.1M+3%$4.6M+38%$4.1M+0%$4.3M+35%$3.8M−7%$4.5M−2%
R&D$2.7M−5%$2.2M−8%$2.2M−18%$2.3M−14%$2.5M−8%$2.8M+26%$2.4M+5%$1.8M−22%$2.5M+4%$2.7M−3%$2.4M+2%$2.4M+35%
SG&A$7M+3%$5.8M−8%$6.5M−4%$7.1M+4%$8M+14%$8.1M+38%$7.6M+18%$7.3M+3%$8.1M+2%$7.3M−10%$7.4M−4%$6.7M−8%
−$5.6M+12%−$5.3M+19%−$4.7M−16%−$6M+14%−$6.3M+13%−$7.6M+44%−$5.9M+25%−$4M−34%−$6.6M+3%−$5.6M−26%−$6M+1%−$4.6M+15%
Interest expensen/an/an/an/an/an/an/an/an/an/an/an/a
Net income−$5.4M+9%−$5M+21%−$4.5M−16%−$5.8M+18%−$6.2M+15%−$7.5M+49%−$5.8M+29%−$3.8M−34%−$6.5M+4%−$5.5M−26%−$5.9M+1%−$4.5M+17%
−$0.07+0%−$0.07+17%−$0.06−14%−$0.07+0%−$0.08+14%−$0.09+29%−$0.07+17%−$0.05−29%−$0.07−13%−$0.06−33%−$0.06−14%−$0.05+0%
82.5M+8%82.7M+8%83.5M+9%84.6M+4%85.8M+4%86.8M+5%87.8M+5%88M+4%92M+7%96M+11%98.9M+13%100M+14%

Net income: Q2 FY16: not printed by the filing, worked out from its own lines.

EPS, diluted: 11 periods, Q4 FY15 to Q4 FY25: quarter's net income to common over its shares, to the cent.

Diluted shares: 12 periods, Q4 FY12 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. Q4 FY14 and Q4 FY16: share-days: the 12-month average less the 9-month, weighted by days.

From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.

Peers

Companies in Healthcare nearest Stereotaxis' size, closest first.

CompanyMarket capPEIts 10y median PEFwd PEP/SRevenue growthNet margin
STXSStereotaxis$88.2Mn/m79.0×2.9×−5%−74.2%
ICCCImmucell$95.9M132×44.1×3.1×+8%2.6%
KEQUKewaunee Scientific$96.7M12.1×13.6×0.3×+5%3.0%
LFVNLifevantage$73.5M14.7×19.4×0.4×−20%2.8%
SPROSpero Therapeutics$60.6M9.5×9.5×1.3×−3%15.7%
APTAlpha Pro Tech$56.3M13.5×14.8×0.9×+6%6.8%
ATNMActinium Pharmaceuticals$45M4.0×3.3×n/mn/mn/m
PDEXPro DEX$184.5M15.9×16.5×2.3×+13%15.1%
PLXProtalix BioTherapeutics$206.3M11.1×33.6×2.6×+30%23.5%
NATRNatures Sunshine Products$211.5M11.9×20.2×0.4×+7%3.7%
NEPHNephros$35.2M20.3×28.3×1.7×+24%8.4%
Peer median$84.7M12.8×18.0×1.3×+7%6.8%

More on Stereotaxis

Each number over time

Its groups

About

Industry
Medical - Devices
Sector
Healthcare

Valuation data, not investment advice. Prices as of .